Breast and gynecological cancers in Croatia, 1988-2008

**Aim** To analyze and interpret incidence and mortality trends of breast and ovarian cancers and incidence trends of cervical and endometrial cancers in Croatia for the period 1988-2008.

**Methods** Incidence data were obtained from the Croatian National Cancer Registry. The mortality data were obtained from the World Health Organization (WHO) mortality database. Trends of incidence and mortality were analysed by joinpoint regression analysis.

**Results** Joinpoint analysis showed an increase in the incidence of breast cancer with estimated annual percent of change (EAPC) of 2.6% (95% confidence interval [CI], 1.9 to 3.4). The mortality rate was stable, with the EAPC of 0.3%. Endometrial cancer showed an increasing incidence trend, with EAPC of 0.8% (95% CI, 0.2 to 1.4), while cervical cancer showed a decreasing incidence trend, with EAPC of -1.0 (95% CI, -1.6 to -0.4). Ovarian cancer incidence showed three trends, but the average annual percent change (AAPC) for the overall period was not significant, with a stable trend of 0.1%. Ovarian cancer mortality was increasing since 1992, with EAPC of 1.2% (95% CI, 0.4 to 1.9), while the trend for overall period was stable with AAPC 0.1%.

**Conclusion** Incidence trends of breast, endometrial, and ovarian cancers in Croatia 1988-2008 are similar to the trends observed in most of the European countries, while the modest decline in cervical cancer incidence and lack of decline in breast cancer mortality suggest suboptimal cancer prevention and control.
Breast and gynecological cancers are among the seven most common female cancers in Croatia: in 2008 breast cancer was the most common cancer with the proportion of 26% of all cancer sites, endometrial cancer ranked fourth (6%), ovarian cancer (with fallopian tubes cancer) sixth (5%), and cervical cancer seventh (4%) (1).

Breast, endometrial, and ovarian cancers share some similar risk factors like early menarche, late menopause, obesity, and low parity (2-5). Also, breast cancer in personal history increases the risk of endometrial and ovarian cancer (6). Delayed childbearing increases the risk of breast cancer but seems to have no impact on the development of ovarian and endometrial cancer (3-5). Diabetes mellitus increases the risk of endometrial and breast cancer (7,8). Use of tamoxifen or other selective estrogen receptor modulators increases the risk of endometrial and ovarian cancer, while the use of combined oral contraceptives is a protective factor (2,9,10). Also, tobacco smoking and alcohol intake reduce the risk of endometrial cancer (2,11,12). Alcohol intake and both oral contraceptives and hormonal replacement therapy are risk factors for breast cancer (2,13,14). Multiparity and physical activity are protective factors for all three cancers (2,4,15,16). Low socioeconomic status, sexually transmitted diseases, promiscuity, unprotected sexual behavior, and smoking are risk factors for cervical cancer (2,17-23). Infection with human papillomavirus is considered as a necessary cause of cervical cancer (24).

The aim of this study was to report the incidence and mortality of breast and ovarian cancers and incidence of endometrial and cervical cancers, analyze the trends in the period 1988-2008, and compare them to other European countries.

MATERIALS AND METHODS

Data sources

Incidence data for the period 1988-2008 were obtained from the Croatian National Cancer Registry. The Registry, founded in 1959, covers the whole Croatian population (approximately 4.4 million persons) and relies on mandatory cancer notifications from primary and secondary health care sources and death certificates from the Croatian Bureau of Statistics. The Registry contributed data to the last three volumes of the Cancer Incidence in Five Continents series (25-27). Breast cancer was classified in the International Classification of Diseases as ICD-10 C50 and ICD-9 174, endometrial cancer as ICD-10 C54 and ICD-9 182, cervical cancer as ICD-10 C53 and ICD-9 180, and ovarian cancer as ICD-10 C56 and ICD-9 183. More than 95% of uterine corpus cancers are endometrial so we referred to all of them as endometrial cancer. The number of breast and ovarian cancer deaths were obtained from the World Health Organization (WHO) mortality database (28). Due to the frequent assignment of “malignant neoplasm of uterus, part unspecified” (ICD-10 C55) as the underlying cause of death in the analyzed period, and consequent underestimation of cervical and endometrial cancer mortality, we did not include these data in the analysis (28).

Statistical analysis

Age-standardized rates (ASR) of cancer incidence and mortality were calculated by the direct standardization method, using the world standard population as a reference (29). To calculate age-specific incidence and mortality rates for breast cancer, we used the United Nations population estimates (30).

To describe incidence and mortality trends by calendar period, we carried out jointpoint regression analysis using the software Joinpoint Regression Program, Version 3.5.2, October 2011 (31). The analysis included the logarithmic transformation of the rates, standard error, maximum number of five joinpoints, and minimum of four years between two joinpoints. All other program parameters were set to default values. The aim of the approach is to identify possible joinpoints where a significant change in the trend occurs. The method identifies joinpoints based on regression models with 0-5 joinpoints. The final model selected was the most parsimonious of these, with the estimated annual percent change (EAPC) based on the trend within each segment (31). To quantify the trend over a fixed number of the years, the average annual percent change (AAPC) was calculated. The AAPC is computed as a geometric weighted average of the EAPC trend analysis, with the weights equal to the lengths of each segment during the prespecified fixed interval.

In describing trends, the terms “significant increase” or “significant decrease” signify that the slope of the trend was statistically significant ($P<0.05$). For non-significant trends ($P>0.05$), we used the terms “stable” (for EAPC between -0.5% and 0.5%), “non-statistically significant increase” (for EAPC >0.5%), and “non-statistically significant decrease” (for EAPC <0.5%). All statistical tests were two sided.

www.cmj.hr
RESULTS

Breast cancer

From 1988 to 2008, the number of new breast cancer cases increased from 1220 to 2472 and ASR of incidence increased from 35.5 to 61.9 per 100,000. The number of deaths increased from 670 to 902, while ASRs remained stable (Table 1).

Joinpoint analysis of incidence showed a significantly increasing trend, with EAPC of 2.6% (95% confidence interval [CI], 1.9 to 3.4). Mortality trend was stable, with EAPC of -0.3% (95% CI, -0.6 to 0.0) (Table 1, Figure 1). When analyzed by 10-year age groups (Table 2), the incidence was increasing in all age groups. A significant change in the incidence trend was most pronounced in 2005 in the 60-69 age group, with EAPC of 14.2% in the period 2005-2008. Mortality decreased in younger age groups (30-49 years) and increased in older age groups (>60 years). In the age group 50-59 years, there was a change in trend starting from 1999. In that age group, mortality was increasing (EAPC 1.7%) from 1988 to 1999, when it started to decrease (EAPC -3.5%).

Endometrial cancer

In 1988 there were 390, and in 2008 520 new cases of endometrial cancer. The ASRs increased from 10.7/100,000 in 1988 to 11.4/100,000 in 2008 (Table 3). Joinpoint analysis revealed a constant and significant increase, with the EAPC of 0.8% (95% CI, 0.2 to 1.4) for the period of 20 years (Table 4, Figure 2).

Ovarian cancer

The number of new ovarian cancer cases increased from 337 in 1988 to 439 in 2008 (Table 3). Trend analysis of ovarian cancer incidence showed three trends (Figure 3, Table 4).

| Year | Incidence N | crude rate | ASR | Mortality N | crude rate | ASR |
|------|-------------|------------|-----|-------------|------------|-----|
| 1988 | 1220        | 52.7       | 35.5| 670         | 28.9       | 18.0|
| 1989 | 1353        | 58.3       | 38.8| 661         | 28.5       | 17.8|
| 1990 | 1461        | 62.7       | 40.7| 710         | 30.5       | 18.4|
| 1991 | 1351        | 57.5       | 37.9| 758         | 32.3       | 19.8|
| 1992 | 1429        | 60.3       | 37.7| 730         | 30.8       | 18.0|
| 1993 | 1539        | 64.3       | 40.6| 758         | 31.7       | 18.4|
| 1994 | 1658        | 68.7       | 43.6| 749         | 31.1       | 17.7|
| 1995 | 1779        | 73.6       | 45.4| 768         | 31.8       | 18.0|
| 1996 | 1782        | 73.8       | 45.8| 706         | 29.3       | 16.9|
| 1997 | 1883        | 78.6       | 47.7| 769         | 32.1       | 17.8|
| 1998 | 1908        | 80.3       | 47.8| 794         | 33.4       | 18.4|
| 1999 | 2544        | 108.1      | 67.4| 856         | 36.4       | 19.7|
| 2000 | 2038        | 87.3       | 51.7| 843         | 36.1       | 18.5|
| 2001 | 2233        | 96.1       | 57.0| 832         | 35.8       | 18.5|
| 2002 | 2052        | 88.6       | 51.1| 804         | 34.7       | 17.1|
| 2003 | 2251        | 97.4       | 55.8| 822         | 35.6       | 16.9|
| 2004 | 2164        | 93.8       | 52.8| 825         | 35.8       | 17.9|
| 2005 | 2303        | 100.0      | 56.2| 922         | 40.0       | 18.0|
| 2006 | 2205        | 95.9       | 54.3| 830         | 36.1       | 17.1|
| 2007 | 2574        | 112.1      | 62.7| 861         | 37.5       | 17.3|
| 2008 | 2472        | 107.9      | 61.9| 902         | 39.4       | 17.6|
Changes in the trend occurred in 1997 and 2000. Between 1988 and 1997, the trend was stable, with EAPC 0.4% (95% CI, -1.2 to 1.9). Between 1997 and 2000, there was a non-significant increase in incidence, with EAPC 8.1% (95% CI, -7.4 to 26.2). Between 2000 and 2008, there was a significant decreasing incidence, with EAPC -3.1% (95% CI, -4.8 to -1.4) (Table 4). AAPC for the overall period was not significant, with a stable trend of 0.1% (95% CI, -2.2 to 2.4).

### Table 2. Joinpoint analysis of breast cancer incidence and mortality in Croatia, 1988-2008 with the estimated annual percent change (EAPC) and 95% confidence intervals (CI)

| Trend 1 (years) | EAPC (95% CI) | Trend 2 (years) | EAPC (95% CI) |
|----------------|---------------|----------------|---------------|
| Incidence by age-group: | | | |
| 30-39 | 1988-2008 | 1.1 (-0.5 to 2.8) | | |
| 40-49 | 1988-2008 | 1.7* (0.6 to 2.7) | | |
| 50-59 | 1988-1999 | 6.2* (4.9 to 7.6) | 1999-2008 | 0 (-1.6 to 1.8) |
| 60-69 | 1988-2005 | 3.0* (2.2 to 3.9) | 2005-2008 | 14.2* (1.7 to 28.3) |
| 70-79 | 1988-1999 | 3.5* (2.4 to 4.7) | 1999-2008 | -0.1 (-1.7 to 1.4) |
| >80 | 1988-2003 | 2.7* (1.5 to 3.8) | 2003-2008 | -3.4 (-8.9 to 2.3) |
| Overall | 1988-2008 | 2.6* (1.9 to 3.4) | | |

| Mortality by age-group: | | | |
| 30-39 | 1988-2008 | -3.2* (-4.8 to -1.5) | | |
| 40-49 | 1988-2008 | -1.5* (-2.5 to -0.5) | | |
| 50-59 | 1988-1999 | 1.7* (0.4 to 3.1) | 1999-2008 | -3.5* (-5.3 to -1.7) |
| 60-69 | 1988-2008 | 0.3 (-0.3 to 0.9) | | |
| 70-79 | 1988-2008 | 0.2 (-0.5 to 1) | | |
| >80 | 1988-2008 | 1.6* (0.9 to 2.3) | | |
| Overall | 1988-2008 | -0.3 (-0.6 to 0) | | |

*Statistically significant trend.

### Table 3. Gynecological cancer incidence and mortality data, Croatia 1988-2008. Number of cases, crude rate, and age standardized rate (ASR) per 100 000 (using world standard population)

| Year | Cervical cancer incidence | Endometrial cancer incidence | Ovarian cancer incidence | Ovarian cancer mortality |
|------|---------------------------|-----------------------------|-------------------------|-------------------------|
| N    | crude rate | ASR | N    | crude rate | ASR | N    | crude rate | ASR | N    | crude rate | ASR |
| 1988 | 406  | 17.5  | 12.2 | 390  | 16.8  | 10.7 | 337  | 14.6  | 9.8  | 230  | 9.93  | 6.60 |
| 1989 | 429  | 18.5  | 13.3 | 382  | 16.5  | 10.1 | 372  | 16.0  | 10.8 | 220  | 9.48  | 5.87 |
| 1990 | 399  | 17.1  | 11.9 | 391  | 16.8  | 10.4 | 393  | 16.9  | 11.3 | 239  | 10.25 | 6.28 |
| 1991 | 340  | 14.5  | 10.3 | 357  | 15.2  | 9.3  | 361  | 15.4  | 9.9  | 227  | 9.66  | 5.65 |
| 1992 | 375  | 15.8  | 11.0 | 389  | 16.4  | 10.0 | 390  | 16.4  | 10.6 | 205  | 8.64  | 5.31 |
| 1993 | 415  | 17.3  | 12.5 | 403  | 16.8  | 10.3 | 397  | 16.6  | 10.8 | 243  | 10.15 | 5.95 |
| 1994 | 405  | 16.8  | 12.0 | 414  | 17.2  | 9.9  | 383  | 15.9  | 10.7 | 229  | 9.49  | 5.86 |
| 1995 | 416  | 17.2  | 11.9 | 469  | 19.4  | 11.2 | 427  | 17.7  | 11.1 | 212  | 8.76  | 5.01 |
| 1996 | 365  | 15.1  | 10.5 | 511  | 21.2  | 11.9 | 418  | 17.3  | 10.5 | 239  | 9.90  | 5.55 |
| 1997 | 394  | 16.4  | 11.2 | 528  | 22.0  | 12.2 | 419  | 17.5  | 10.9 | 241  | 10.05 | 5.56 |
| 1998 | 358  | 15.1  | 10.2 | 475  | 20.0  | 10.9 | 426  | 17.9  | 10.7 | 255  | 10.74 | 5.88 |
| 1999 | 403  | 17.1  | 11.4 | 578  | 24.6  | 13.3 | 537  | 22.8  | 13.8 | 279  | 11.86 | 6.27 |
| 2000 | 426  | 18.2  | 12.7 | 508  | 21.8  | 11.9 | 550  | 23.6  | 14.5 | 267  | 11.43 | 6.01 |
| 2001 | 320  | 13.8  | 9.7  | 477  | 20.5  | 10.8 | 516  | 22.2  | 13.1 | 311  | 13.39 | 6.90 |
| 2002 | 363  | 15.7  | 10.7 | 488  | 21.1  | 11.0 | 489  | 21.1  | 12.1 | 289  | 12.48 | 6.37 |
| 2003 | 314  | 13.6  | 9.1  | 471  | 20.4  | 10.6 | 466  | 20.2  | 11.7 | 275  | 11.90 | 5.97 |
| 2004 | 330  | 14.3  | 9.8  | 509  | 22.1  | 11.3 | 432  | 18.7  | 10.7 | 278  | 12.05 | 6.15 |
| 2005 | 320  | 13.9  | 9.4  | 479  | 20.8  | 10.9 | 490  | 21.3  | 12.2 | 287  | 12.46 | 5.94 |
| 2006 | 345  | 15.0  | 10.4 | 534  | 23.2  | 12.0 | 450  | 19.6  | 11.1 | 291  | 12.66 | 6.16 |
| 2007 | 387  | 16.9  | 11.3 | 572  | 24.9  | 12.7 | 468  | 20.4  | 12.0 | 299  | 13.03 | 6.42 |
| 2008 | 359  | 15.7  | 10.2 | 520  | 22.7  | 11.4 | 459  | 19.2  | 10.5 | 326  | 14.23 | 7.09 |
Joinpoint analysis of ovarian cancer mortality revealed two trends. Trend 1 showed a non-significant decrease, with EAPC -4.12% (95% CI, -10.2 to 2.3). Trend 2 showed a significant increase of EAPC 1.2% (95% CI, 0.4 to 1.2%). AAPC for the overall period was not significant, with a stable trend of 0.1% (95% CI, -1.2 to 1.4).

Cervical cancer

In the period 1988-2008, the number of new cervical cancer cases decreased from 406 to 359, or with ASR of 16% – from 12.2/100 000 to 10.2/100 000 (Table 3). Joinpoint trend analysis showed a decrease in the incidence with a significant annual change of -1.0%, (95% CI, -1.6 to -0.4) (Table 4, Figure 4).

**TABLE 4.** Joinpoint analyses of gynecological cancers incidence and mortality in Croatia, 1988-2008, with the estimated annual percent change (EAPC) and 95% confidence intervals (CI)

| Trend segment      | Lower endpoint | Upper endpoint | EAPC (95% CI) |
|--------------------|----------------|----------------|---------------|
| Cervical cancer incidence 1 | 1988   | 2008  | -1.0* (-1.6 to -0.4) |
| Endometrial cancer incidence 1 | 1988   | 2008  | 0.8* (0.2 to 1.4) |
| Ovarian cancer incidence 1 | 1988   | 1997  | 0.4 (-1.2 to 1.9) |
| 2 | 1997   | 2000  | 8.1 (-7.4 to 26.2) |
| 3 | 2000   | 2008  | -3.1* (-4.8 to -1.4) |
| Ovarian cancer mortality 1 | 1988   | 1992  | -4.1 (-10.2 to 2.3) |
| 2 | 1992   | 2008  | 1.2* (0.4 to 1.9) |

*Statistically significant trend.

**FIGURE 3.** Joinpoint analysis of incidence and mortality of ovarian cancer in Croatia, 1988-2008. Rhomb – incidence; triangle – mortality; ASR (W) – age-standardized rate per 100 000 (using world standard population).

**FIGURE 4.** Joinpoint analysis of incidence of cervical cancer in Croatia, 1988-2008. ASR (W) – age-standardized rate per 100 000 (using world standard population).

**DISCUSSION**

Breast cancer

According to our results and GLOBOCAN estimates for 2008 (32), Croatia is among the European countries with an intermediate breast cancer incidence and mortality. The increasing incidence trend in Croatia 1988-2008 is comparable to trends in other European countries. Thirty-five countries with Caucasian majority population showed an increase in the incidence of breast cancer in the period 1990-2002, particularly in Central and Eastern European countries. The increase was slightly higher in the countries with initially lower incidence (33).

Possible explanations for the increase in the incidence in Croatia are a higher prevalence of lifestyle-associated risk factors and improvements in diagnostics. For example, proportion of overweight women increased from 42.9% in 1997 to 58.2% in 2003, the average age at first birth increased from 23.5 years in 1960 to 27.4 years in 2009, and the fertility rate decreased from 2.9 in 1950 to 1.5 in 2009 (34,35). Also, the increase may have been affected by a higher prevalence of alcohol consumption and the use of hormonal replacement therapy and oral contraceptives. The use of hormonal replacement therapy and oral contraceptives in Croatia is lower than in most European countries, but average alcohol intake is among the highest in Europe (36-38).
Croatian national breast cancer screening programme “Mamma” was introduced in 2006. It includes women aged 50-69 years. In the first screening cycle, 720,982 women were invited to mammography screening, with the response of 63% and more than 1500 detected breast cancers (39). The national screening program could have affected the increase in the incidence that appeared in the age group 60-69 years after 2005. However, the lack of similar increase in the age group 50-59 years does not confirm this hypothesis.

Besides its influence on the incidence, the national screening program is also expected to reduce mortality. Countries with long-standing breast cancer screening program had reduced mortality in the screened population (40-42). However, the screening-related reduction in mortality is expected to occur in Croatia in the next 5-10 years (40-42).

Interestingly, in some countries the decline in breast cancer mortality had started before screening was introduced and occurred in non-screened population. Also, declines in mortality were also observed in countries without national screening programs (42). Similarly, the highest decline in mortality in our study was found in younger age groups. Also the decrease in mortality in the age-group 50-59 years started in 1999, before the introduction of the screening program, which could probably be attributed to improved breast cancer care.

Endometrial and ovarian cancer

Gynecological cancers in different European countries exhibit very different incidence trends. A study of geographic and temporal variations of endometrial cancer incidence in 13 European countries in the period from 1964 to 2000 (43) found increasing trends in Iceland, the Netherlands, Czech Republic, Slovakia, Slovenia, Finland, Norway, Sweden, United Kingdom, Spain, and Poland with EAPCs from 0.8 to 3.4% for menopausal women. Decreasing incidence trends were reported for Italy, Switzerland, and Denmark, with EAPCs from -0.8 to -1.1%, while Germany had stable incidence. The increasing incidence trend of endometrial cancer in Croatia with EAPC of 0.8% is similar to most of the European countries.

According to GLOBOCAN 2008 estimates, Croatia is among the 20 countries in Europe with the highest incidence of ovarian cancer (32). The countries that had a high incidence of ovarian cancer in 1960s and 1970s, like Nordic countries, Austria, Germany, and United Kingdom, nowadays show a declining incidence, while Southern and Eastern European countries show an increasing incidence (44). Our trend analysis for Croatia showed a stable incidence trend, with AAPC of 0.1%.

Increasing endometrial cancer incidence and high ovarian cancer incidence in Croatia could be explained by an increasing prevalence of factors such as obesity and low parity. Growing obesity is an important public health problem. A recent study reported that 34% Croatian women are overweight (45). Another risk factor for endometrial cancer is diabetes mellitus, the total prevalence of which in adults in Croatia is high (8.9%) and growing (46). At the same time, oral contraception, which was associated with a decreased risk for endometrial and ovarian cancer, is rarely used (37). However, a significant decrease in the incidence of ovarian cancer in the period 2000-2008 could possibly be explained by an increased use of oral contraception since 1980s, but there are no scientific data to corroborate it. This decreasing incidence trend has not yet reflected on morality, which has had a significantly increasing trend since 1992, with EAPC of 1.2%, in contrast to the trends observed in most of the other European populations (44). Also, the ASR remains high, placing Croatia among the countries with the highest ovarian cancer mortality in Europe (32).

Cervical cancer

According to GLOBOCAN 2008 estimates, Croatia has an intermediate ASR of cervical cancer (32). From the middle 1990s to early 2000s, the rates of cervical cancer were highest in Central Europe, the lowest in Finland, Italy, and Malta, and stable in Nordic countries, Ireland, Austria, and the Netherlands (47). The largest decrease in incidence was observed in countries with organized screening programs like Finland and the Netherlands (48).

The introduction of the Pap smear, which detects premalignant lesions of the cervix and early stages of cervical cancer, reduced the incidence and mortality in developed countries (49). In Croatia, Pap smears were introduced in 1950s (50) and became part of the routine gynecological examination. This led to a decrease in incidence, but an even greater decrease could be achieved through an organized screening program. The Finnish model of organized Pap screening program shows to which extent it is possible to decrease cervical cancer incidence (51). In addition to an 80% reduction in cervical cancer incidence in the age-group 30-64 years, which can be achieved by organized screening (51), further decrease could
be achieved by the use of HPV vaccines against oncogenic types (52). HPV vaccines have been available in Croatia since 2007, but vaccination is not obligatory (53). HPV vaccines cannot replace cytological screening for cervical cancer and their influence on cervical cancer incidence is yet to be seen (54). Croatia already has screening programs for breast and colorectal cancers (39) and the introduction of a screening program for cervical cancer is planned for the near future. However, more investment in cancer prevention is needed, in terms of reducing the exposure to highly prevalent lifestyle risk factors and maintaining or introducing high-quality national screening programs for breast and cervical cancers.

Funding This study was partly supported by the Croatian Ministry of Science, Education, and Sports grant No. 005-1080315-0294.

Ethical approval Not required.

Declaration of authorship K participated in data collection, data analysis, interpretation of the results, manuscript preparation, manuscript editing, and manuscript review. KT participated in interpretation of results, manuscript preparation, manuscript editing, and manuscript review. MK participated in interpretation of results, manuscript preparation, manuscript editing, and manuscript review. PP participated in the interpretation of the results, manuscript preparation, manuscript editing, and manuscript review. IK participated in data collection, data analysis, interpretation of the results, manuscript preparation, manuscript editing, and manuscript review. AC participated in interpretation of results, manuscript preparation, manuscript editing, and manuscript review. MK participated in interpretation of the results and manuscript editing. TK participated in data collection, data analysis, manuscript preparation, manuscript editing, and manuscript review. AZ participated in study design and coordination, interpretation of the results, manuscript preparation, manuscript editing, and manuscript review.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1 Croatian National Cancer Registry. Cancer incidence in Croatia 2008. Bulletin No 33. Zagreb: Croatian National Institute of Public Health; 2010.
2 Riek G, Flander A. The effect of lifestyle factors on gynaecological cancer. Best Pract Res Clin Obstet Gynaecol. 2006;20:227-51. Medline:16543119 doi:10.1016/j.bpbgyyn.2005.10.010
3 Chiavarrino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol. 2001;12:337-41. Medline:11332145 doi:10.1093/ije/31.11.284
4 Parsa P, Parsa B. Effects of reproductive factors on risk of breast cancer: a literature review. Asian Pac J Cancer Prev. 2009;10:545-50. Medline:19827866
5 Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst. 1977;59:1055-60. Medline:333120
6 Yadav BS, Sharma SC, Patel FD, Ghoshal S, Kapoor R, Kumar R. Nonbreast second malignancies after treatment of primary breast cancer. Int J Radiat Oncol Biol Phys. 2009;73:1489-92. Medline:18804919 doi:10.1016/j.ijrobp.2008.07.004
7 Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16:276-80. Medline:17301260 doi:10.1158/1055-9966.EPI-06-0751
8 Suh S, Kim KW. Diabetes and cancer: is diabetes causally related to cancer? Diabetes Metab J. 2011;35:193-8. Medline:21785737 doi:10.4093/dmj.2011.35.3.193
9 Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, et al. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol. 2011;126:78-86. Medline:21600284 doi:10.1016/j.jsbmb.2011.05.001
10 Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives—findings in a large cohort study. Br J Cancer. 1995;71:1340-2. Medline:7779735 doi:10.1038/bjc.1995.260
11 Viswanathan AN, Feskanich D, De Vivo I, Hunter DJ, Barbieri RL, Rosner B, et al. Smoking and the risk of endometrial cancer: results from the Nurses’ Health Study. Int J Cancer. 2005;114:996-1001. Medline:16564590 doi:10.1002/ijc.20821
12 Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med. 2008;121:501-8e3. Medline:18501231 doi:10.1016/j.amjmed.2008.01.044
13 Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87:827-35. Medline:7791322 doi:10.1093/jnci/87.11.827
14 Chlebowski RT, Kalser LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360:573-87. Medline:19196674 doi:10.1056/NEJMoa0807684
15 Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst. 2004;96:1635-8. Medline:15523093 doi:10.1093/jnci/djh291
16 Inumaru LE, Silveira EA, Naves MM. Risk and protective factors for breast cancer: a systematic review. Cad Saude Publica. 2011;27:1259-70. Medline:21808811 doi:10.1590/S0102-311X2011000700002
17 Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodill A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer.
44 Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer. 2005;113:977-90. Medline:15505879 doi:10.1002/ijc.20649

45 Heim I, Leontic K, Gostovic MJ. Obesity and overweight in Croatia [in Croatian]. Acta Med Croatica. 2007;61:267-73. Medline:17629101

46 Metelko Z, Pavlic-Renar I, Poljicanin T, Szirovitz L, Turek S. Prevalence of diabetes mellitus in Croatia. Diabetes Res Clin Pract. 2008;81:263-7. Medline:18534707 doi:10.1016/j.diabres.2008.04.016

47 Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345-89. Medline:18280139 doi:10.1016/j.ejca.2007.12.015

48 Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol. 2007;18:1423-5. Medline:17693658 doi:10.1093/annonc/mdm377

49 Papanicolaou GN, Taut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Arch Pathol Lab Med. 1997;121:211-24. Medline:9111103

50 Znaor A, Strnad M. Cervical cancer in Croatia: state of the art and possibilities for prevention. Coll Antropol. 2007;31 Suppl 2:37-40. Medline:17598503

51 Anttila A, Nieminen P. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. Coll Antropol. 2007;31 Suppl 2:17-22. Medline:17600933

52 Gissmann L, Muller M. Development of prophylactic HPV vaccines. Coll Antropol. 2007;31 Suppl 2:113-5. Medline:17598512

53 Kaic B, Gjenero-Margan I, Brzovic M, Lakoseljac D, Aleraj B, Nemeth-Blazic T, et al. Vaccine regulations in Croatia. Coll Antropol. 2007;31 Suppl 2:117-20. Medline:17598513

54 Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24 Suppl 3:53/171-7. Medline:16844268 doi:10.1016/j.vaccine.2006.05.061